Literature DB >> 16127800

Results of second-look resection after primary resection of T1 tumour of the urinary bladder.

Staffan Jahnson1, Fredrik Wiklund, Milos Duchek, Oddvar Mestad, Erkki Rintala, Sverker Hellsten, Per-Uno Malmström.   

Abstract

OBJECTIVE: To study residual tumours at second-look resection in patients resected 4-8 weeks earlier for T1 tumours of the urinary bladder.
MATERIAL AND METHODS: All patients randomized in the ongoing Nordic T1G2-G3 Bladder Sparing Study with monitored data available were included in the study. Data on residual tumours at second-look resection were compared to basic patient and tumour characteristics.
RESULTS: There were 72 patients (56%) without and 57 with residual exophytic tumours. In the former group, 20 patients (28%) had carcinoma in situ, compared to 19 (33%) in the latter group. Potentially dangerous tumours (either carcinoma in situ, T1 or Ta grade 3) were observed in 55 patients (43%). Multiple tumours at primary resection were more prone to residual tumour at second-look resection than single tumours. No other tumour or patient characteristics could predict the occurrence of a residual tumour.
CONCLUSIONS: Residual tumours are frequently observed at second-look resection 4-8 weeks after primary resection of T1 tumours. The majority of residual tumours detected at this stage are potentially dangerous; therefore, early second-look resection followed by intravesical instillation therapy is mandatory in patients with T1 tumours of the urinary bladder.

Entities:  

Mesh:

Year:  2005        PMID: 16127800     DOI: 10.1080/00365590510007793-1

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  11 in total

Review 1.  Optimal treatment of non-muscle invasive urothelial carcinoma including perioperative management revisited.

Authors:  Matthew J Pagano; Gina Badalato; James M McKiernan
Journal:  Curr Urol Rep       Date:  2014-11       Impact factor: 3.092

2.  Saudi Oncology Society clinical management guidelines for urinary bladder cancer.

Authors:  Khaled Al Othman; Shouki Bazarbashi; Khalid Balaraj; Mohamed Al Otaibi; Baher Kamal; Ibraheem Al Oraifi; Eyad Al Saeed; Khalid Al Gamdi; Ali Jubran; Ahmad Salah; Jalal Al Shareef; Jamal Zekri
Journal:  Urol Ann       Date:  2011-03

Review 3.  High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.

Authors:  Oscar Rodriguez Faba; Joan Palou; Alberto Breda; H Villavicencio
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

Review 4.  Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.

Authors:  Siamak Daneshmand; Anne K Schuckman; Bernard H Bochner; Michael S Cookson; Tracy M Downs; Leonard G Gomella; H Barton Grossman; Ashish M Kamat; Badrinath R Konety; Cheryl T Lee; Kamal S Pohar; Raj S Pruthi; Matthew J Resnick; Norm D Smith; J Alfred Witjes; Mark P Schoenberg; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2014-09-23       Impact factor: 14.432

5.  Saudi oncology society and Saudi urology association combined clinical management guidelines for urothelial urinary bladder cancer.

Authors:  Mubarak Al-Mansour; Ahmad Saadeddin; Sultan Alkhateeb; Ashraf Abusamra; Danny Rabah; Mohammed Alotaibi; Esam Murshid; Abdullah Alsharm; Imran Ahmad; Khalid Alghamdi; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2014-10

Review 6.  How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

Authors:  Seok Joong Yun; Seon-Kyu Kim; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2016-06-10

Review 7.  Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder.

Authors:  Sultan Alkhateeb; Mubarak Al-Mansour; Mohammed Alotaibi; Ahmad Saadeddin; Ashraf Abusamra; Danny Rabah; Esam Murshid; Abdullah Alsharm; Imran Ahmad; Hussain Kushi; Abdullah Alghamdi; Khalid Alghamdi; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2016 Apr-Jun

Review 8.  Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017.

Authors:  Hulayel Alharbi; Sultan Alkhateeb; Esam Murshid; Mohammed Alotaibi; Ashraf Abusamra; Danny Rabah; Mubarak Almansour; Abdullah Alghamdi; Ali Aljubran; Amin Eltigani; Hussein Alkushi; Imran Ahmed; Abdullah Alsharm; Shouki Bazarbashi
Journal:  Urol Ann       Date:  2018 Apr-Jun

9.  Is there a role for second transurethral resection in pTa high-grade urothelial bladder cancer?

Authors:  Anuj Deep Dangi; Ramani Manoj Kumar; Thomas Alex Kodiatte; Mahasampth Gowri; Santosh Kumar; Antony Devasia; Nitin Kekre
Journal:  Cent European J Urol       Date:  2018-06-12

10.  Utility of restage transurethral resection of bladder tumor.

Authors:  Vignesh Manoharan; Ravimohan Suryanarayan Mavuduru; Santosh Kumar; Nandita Kakkar; Sudheer Kumar Devana; Girdhar Singh Bora; Shrawan Kumar Singh; Arup Kumar Mandal
Journal:  Indian J Urol       Date:  2018 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.